To Top


Company Information

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company committed to the development of first-in-class, effective therapies that harness the power of the tumor microenvironment (TME) to overcome drug resistance and improve treatment outcomes for cancer patients.

Stock Info

Corporate Presentation

Stock Chart

News and Events

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
January 9 2023 at 8:00 am - January 12 at 5:00 pm - UTC+0
November 15 2022 at 8:00 am - November 17 at 5:00 pm - UTC+0
April 8 2022 at 8:00 am - 5:00 pm - UTC+0
August 9 2021 at 8:00 am - August 10 at 5:30 pm - UTC+0
June 4 2021 at 12:00 am - June 8 at 11:59 pm - UTC+0
January 20 2021 at 10:30 am - 11:00 am - UTC+0

Press Releases

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219 exposu...
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that h...
Purple Biotech Reports Second Quarter 2023 Financial Results
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway exte...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
Purple's innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (...
Purple Biotech Debuts Scientific Advisory Board
Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE...
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd...
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- Purp...
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dura...
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech L...
First | Previous | Next  | Last

SEC Filings

Shareholders' Meetings

Date Files
June 15, 2023 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS Report of Foreign Private Issuer Report of Foreign Private Issuer
August 25, 2022 ea163003-6k_purplebioEDGAR2_Bannerless Instructions-and-Voting-Card-for-2022-GM PURPLE-BIOTECH-LTD-VIF
Dec 22, 2021 Purple-Biotech-Ltd_6-K_Voting-Slip Purple-Biotech-Ltd_6-K_Notice-and-Proxy-Statement 17865-PURPLE-BIOTECH-LTD-KITOV-VIF

Email alerts

Corporate Governance

Purple Biotech Ltd.’s Board of Directors sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Corporate Governance Documents
Code of Ethics Download
Audit Committee Charter Download
Compensation Committee Charter Download
Board Diversity Matrix Download
Audit Committee Compensation Committee
Independent Directors
Dr. Eric Rowinsky
Simcha Rock icon-member icon-member
Ido Agmon icon-member-chair-person
Steven Steinberg icon-member-chair-person
Robert Gagnon icon-member
Suzana Nahum-Zilberberg icon-member
Ori Hershkovitz
Non-independent Directors
Isaac Israel
icon-memberMember icon-chair-personChair
Skip to content